DE69624259T2 - Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel - Google Patents

Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel

Info

Publication number
DE69624259T2
DE69624259T2 DE69624259T DE69624259T DE69624259T2 DE 69624259 T2 DE69624259 T2 DE 69624259T2 DE 69624259 T DE69624259 T DE 69624259T DE 69624259 T DE69624259 T DE 69624259T DE 69624259 T2 DE69624259 T2 DE 69624259T2
Authority
DE
Germany
Prior art keywords
growth factor
antiidotypical
antibodies
cell growth
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624259T
Other languages
English (en)
Other versions
DE69624259D1 (de
Inventor
Jean Plouet
Frederic Jonca
Nathalie Ortega
Marie-Magdeleine Ruchoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE69624259D1 publication Critical patent/DE69624259D1/de
Publication of DE69624259T2 publication Critical patent/DE69624259T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69624259T 1995-12-21 1996-12-20 Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel Expired - Fee Related DE69624259T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9515243A FR2742662B1 (fr) 1995-12-21 1995-12-21 Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments
PCT/FR1996/002041 WO1997023510A1 (fr) 1995-12-21 1996-12-20 Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments

Publications (2)

Publication Number Publication Date
DE69624259D1 DE69624259D1 (de) 2002-11-14
DE69624259T2 true DE69624259T2 (de) 2003-09-18

Family

ID=9485786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624259T Expired - Fee Related DE69624259T2 (de) 1995-12-21 1996-12-20 Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel

Country Status (8)

Country Link
US (2) US6887469B2 (de)
EP (1) EP0868434B1 (de)
JP (1) JP2000506501A (de)
AT (1) ATE225809T1 (de)
DE (1) DE69624259T2 (de)
ES (1) ES2184901T3 (de)
FR (1) FR2742662B1 (de)
WO (1) WO1997023510A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
AU2994599A (en) * 1998-03-06 1999-09-20 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
JP2002529421A (ja) * 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
AU1804201A (en) * 1999-12-02 2001-06-12 Zymogenetics Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
AU2003265057A1 (en) * 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
MXPA05009044A (es) 2003-02-20 2006-03-17 Macropore Biosurgery Inc Metodos para utilizar celulas derivadas de tejido adiposo en el tratamiento de condiciones cardiovasculares.
WO2005011569A2 (en) 2003-06-18 2005-02-10 Macropore Biosurgery Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
FR2858326A1 (fr) * 2003-08-01 2005-02-04 Abtech Procede de preparation d'anticorps mimetiques d'une substance et les anticorps ainsi obtenus
WO2005034843A2 (en) 2003-09-17 2005-04-21 Macropore Biosurgery Inc. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
PL1778833T3 (pl) 2004-07-01 2011-10-31 Cytori Therapeutics Inc Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
ES2364689T3 (es) 2005-05-25 2011-09-12 Cytori Therapeutics, Inc. Procedimiento de uso de células derivadas de tejido adiposo en el tratamiento de afecciones cardiovasculares.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US4737453A (en) * 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
DK0502416T3 (da) * 1991-04-03 1998-01-12 American Cyanamid Co Stimulering af vækst med anti-idiotypiske antistoffer frembragt mod et antistof specifikt for porcint somatotropin
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis

Also Published As

Publication number Publication date
FR2742662B1 (fr) 1998-01-23
EP0868434A1 (de) 1998-10-07
US20020131966A1 (en) 2002-09-19
FR2742662A1 (fr) 1997-06-27
US6887469B2 (en) 2005-05-03
DE69624259D1 (de) 2002-11-14
ES2184901T3 (es) 2003-04-16
JP2000506501A (ja) 2000-05-30
US20050112062A1 (en) 2005-05-26
WO1997023510A1 (fr) 1997-07-03
EP0868434B1 (de) 2002-10-09
ATE225809T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
DE69624259D1 (de) Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel
WO1997019111A3 (es) Anticuerpos monoclonales anti-cd6 y sus utilizaciones
DE59813875D1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
ATE193553T1 (de) Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ES2146627T3 (es) Metalocenos de bis-fluorenilo y su uso.
EP1746160A3 (de) Hepatozyt-Wachstumsfaktor-Rezeptor-Antagonisten und deren Anwendung
ATE148172T1 (de) Rahmenbau-mutierte antikörper und ihre herstellung
YU28897A (sh) Biciklicno kondenzovani piridini
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
TR200102493T2 (tr) IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE59504707D1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
ATE444963T1 (de) Neue n-benzyldioxol-imidazolderivate, verfahren zu ihrer herstellung, erhaltene zwischenprodukte, pharmazeutische zusammensetzungen und ihre verwendung als endothelin-antagonisten
AU7509300A (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
DE68926899D1 (de) Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE293685T1 (de) Monoklonaler antikörper gegen ratte beta-2- integrin alpha d untereinheit und entsprechendes hybridoma
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee